LYELL IMMUNOPHARMA
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
LYELL IMMUNOPHARMA
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Status:
Active
Contact:
1 650-695-0677
Total Funding:
493 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Mobile Non Scaleable Content Nginx Amazon IPv6
Similar Organizations
Adyn
Adyn is a precision medicine company that develops personalized birth control methods.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Cerespir
Cerespir is an operator of a biotechnology company intended to treat neurodegenerative disorders.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
ESSA Pharma
ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Instil Bio
Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Kallyope
Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Olema Oncology
Olema Oncology is a preclinical biotechnology company that develops new drugs for the treatment and prevention of breast cancer.
Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.
PanTheryx
PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.
PocketPills
Pocketpills is an online pharmacy that provides medication and refill transfers.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
The Public Health Company
The Public Health Company is a biotechnology firm that offers a platform for genomic epidemiology scientists to outbreak intelligence.
Toregem BioPharma
Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia.
Triumvira Immunologics
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Employees Featured
Founder
Stock Details
Investors List
Sahsen Ventures
Sahsen Ventures investment in Series A - Lyell Immunopharma
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series A - Lyell Immunopharma
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Lyell Immunopharma
Arrive
Arrive investment in Series A - Lyell Immunopharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-31 | Outpace Bio | Lyell Immunopharma investment in Series A - Outpace Bio | 30 M USD |
| 2020-09-30 | Sonoma Pharmaceuticals | Lyell Immunopharma investment in Post-IPO Equity - Sonoma Pharmaceuticals | 70 M USD |
| 2020-09-30 | Sonoma BioTherapeutics | Lyell Immunopharma investment in Series A - Sonoma BioTherapeutics | 30 M USD |
| 2020-03-18 | Cero Therapeutics | Lyell Immunopharma investment in Series A - Cero Therapeutics | 40 M USD |
| 2020-03-17 | Eureka Therapeutics | Lyell Immunopharma investment in Series E - Eureka Therapeutics | 45 M USD |
| 2020-02-06 | Sonoma BioTherapeutics | Lyell Immunopharma investment in Series A - Sonoma BioTherapeutics | 40 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-31 | Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer |
More informations about "Lyell Immunopharma"
Pioneering Transformative T-Cell Therapies | Lyell
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients. Join our team of ambitious Lyellites who are committed to …See details»
Our Team - Lyell
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. We are pioneering novel T-cell reprogramming technologies designed to address major barriers to …See details»
Our Story - Lyell
Lyell is a clinical-stage cell therapy company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors and hematologic malignancies. We are pioneering …See details»
Cellares and Lyell to Evaluate Automated …
Sep 11, 2023 · SOUTH SAN FRANCISCO, September 11, 2023 – Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell …See details»
Lyell Immunopharma - Crunchbase Investor Profile
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with …See details»
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
Oct 31, 2024 · Lyell will accelerate the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, …See details»
Investor Relations - Lyell Immunopharma, Inc.
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors.See details»
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio …
Oct 25, 2024 · Lyell Immunopharma has entered a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company specialising in chimeric antigen receptor (CAR)-T cell therapies. Concurrently, …See details»
Lyell loses 25% of staff, CMO to conserve cash post-GSK collab
Nov 8, 2023 · A year after Lyell Immunopharma lost a $1 billion biobucks partnership with GSK, the cell therapy biotech is offloading a quarter of its staff and deprioritizing some earlier-stage …See details»
Lyell Immunopharma – $425 Million IPO - cooley.com
San Francisco – July 20, 2021 – Cooley advised Lyell Immunopharma, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, on its $425 million initial public offering of 25,000,000 shares of …See details»
Our Pipeline - Lyell
Lyell has immense potential to target aggressive malignancies. Our diverse pipeline targets B-cell lymphoma, triple-negative breast cancer, non-small cell lung cancer, ovarian cancer and endometrial cancer — but these initial …See details»
News Release Details - Lyell Immunopharma, Inc.
Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy …See details»
Lyell Immunopharma - Funding, Financials, Valuation & Investors
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.See details»
GSK and Lyell Immunopharma join forces to develop the next …
Oct 8, 2019 · GlaxoSmithKline plc today announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to …See details»
Lyell Immunopharma Reports First Quarter Financial Results and …
SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Lyell) (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T …See details»
Lyell Immunopharma, Inc. (LYEL) - Yahoo Finance Canada
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors.See details»
Why Lyell Immunopharma Shares Are Rising Today
Nov 10, 2023 · Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares are trading higher after the company announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug …See details»
Lyell Immunopharma (LYEL) Earnings Date and Reports 2024
Oct 21, 2024 · Lyell Immunopharma released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.17, which topped the consensus estimate of -$0.20 by $0.03. Quarterly revenue …See details»
El director de Lyell Immunopharma, Hans Bishop, renuncia
2 days ago · Lyell Immunopharma, Inc. (NASDAQ:LYEL), una empresa biofarmacéutica especializada en el desarrollo de nuevas inmunoterapias contra el cáncer, anunció la renuncia …See details»
Our Cell Therapies | Lyell
We are committed to developing transformative cell therapies to improve outcomes for patients with cancer. Our body’s immune system can recognize cancer cells as abnormal and kill them. …See details»